SIRIUS-BIOTECH ACQUIRED A NOVEL ANTI HUMAN PERIOSTIN MONOCLONAL ANTIBODY WITH INHIBITORY ACTIVITY ON TUMOR GROWTH AND ANGIOGENESIS

Sirius-biotech has acquired from the National Cancer Institute of Genoa a novel anti-periostin antibody, OC-20, that shows inhibitory effects on tumor growth and angiogenesis in vivo in tumor-bearing mice.

OC-20 reacts with an epitope localised in the second FAS1 domain (FAS1-2) of periostin. This epitope is a new cell binding site of perostin, interacting with the integrins αvβ3 and αvβ5.

Orecchia et al. (2011) “Identification of a novel cell binding site of periostin involved in tumour growth.” Eur J Cancer 47:2221-9.